[1] GAO FF, LI F.Analysis on the characteristics and risk factors of senile malignant tumors in China[J]. Geriatrics & Health Care(老年医学与保健), 2018, 24(6): 729-731. [2] PENG YF, ZHANG YW, YE TS, et al.A preliminary study on professor Zhang Yingwen’s academic thoughts on diagnosis and treatment of tumor[J]. World Chinese Medicine(世界中医药), 2017, 12(11): 2720-2723. [3] HE ZQ, ZHANG J, LI YH, et al.Study on anticancer effect of elemene injectable emulsion[J]. Practical Oncology Journal(实用肿瘤学杂志), 2003(4): 258-260. [4] YANG W, XIE Y, ZHUANG Y.Based on HIS“real world”data warehouse to explore the safety evaluation method of Chinese patent medicine after market[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2011, 36(20): 2779-2782. [5] CHEN WB, PAN XL.Diagnostics(诊断学)[M]. 7th ed. Beijing: People’s Medical Publishing House, 2008. [6] World Health Organization.International Statistical Classification of Diseases and health-related Problems (10th revision)(疾病和有关健康问题的国际统计分类(第10次修订本))[M] //DONG JW. 2nd ed. Beijing: People’s Medical Publishing House, 2008. [7] GB/T 16751B/T 16751.2-1997. TCM Clinical Diagnosis and Treatment Terms-Syndrome Part(中医临床诊疗术语证候部分)[S]. Beijing: Standards Press of China, 1997. [8] ZHENG RS, SUN KX, ZHANG SW, et al.Prevalence of malignant tumors in China in 2015[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2019, 41(1): 19-28. [9] WANG H, HOU W, SUN GZ, et al.Investigation on characteristics of TCM deficiency syndrome in patients with advanced malignant tumor malnutrition[J]. World Chinese Medicine(世界中医药), 2016, 11(12): 2793-2796. [10] YANG Y, WEI GH, XU CM, et al.Luo Yi’s experience in the treatment of malignant tumors[J]. Henan Traditional Chinese Medicine(河南中医), 2021, 41(10): 1538-1541. [11] GUO P, ZHU WK, LI Y, et al.Clinical observation on the efficacy and safety of elemene emulsion in the treatment of advanced liver cancer[J]. World Chinese Medicine(世界中医药), 2018, 13(3): 676-678, 682. [12] ZHAO YS, ZHAO X.Clinical observation of elemene injectable emulsion, NP regimen, and comprehensive treatment of advanced non-small cell lung cancer with thalidomide[J]. Chinese Folk Remedies(中国民间疗法), 2021, 29(3): 104-106. [13] XIE YM, WANG LX, WANG YY.Study on mechanism of clinical combined drug use[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2014, 39(18): 3424-3426. [14] JIN XY, ZHENG WK, ZHANG JH, et al.Promote transparency in real-world research[J]. World Chinese Medicine(世界中医药), 2019, 14(12): 3106-3110. [15] YANG W, XIE YM, ZHUANG Y.Based on HIS“real world”data warehouse to explore the safety evaluation method of Chinese patent medicine after market[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2011, 36(20): 2779-2782. [16] WANG GQ, SUN SL, XIE YM, et al.Common problems and optimization measures of TCM clinical research program design[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2017, 32(3): 935. |